We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Sanofi (SNY - Free Report) closed at $50.85 in the latest trading session, marking a +0.08% move from the prior day. This move outpaced the S&P 500's daily loss of 0.78%. Meanwhile, the Dow lost 1.09%, and the Nasdaq, a tech-heavy index, added 0.29%.
Investors will be hoping for strength from SNY as it approaches its next earnings release. The company is expected to report EPS of $0.70, down 5.41% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.44 billion, down 2.6% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.38 per share and revenue of $41.84 billion. These totals would mark changes of +1.81% and +3.5%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for SNY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.69% lower. SNY is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that SNY has a Forward P/E ratio of 15.02 right now. This valuation marks a discount compared to its industry's average Forward P/E of 15.2.
It is also worth noting that SNY currently has a PEG ratio of 2.07. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.07 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 17, which puts it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Gains As Market Dips: What You Should Know
Sanofi (SNY - Free Report) closed at $50.85 in the latest trading session, marking a +0.08% move from the prior day. This move outpaced the S&P 500's daily loss of 0.78%. Meanwhile, the Dow lost 1.09%, and the Nasdaq, a tech-heavy index, added 0.29%.
Investors will be hoping for strength from SNY as it approaches its next earnings release. The company is expected to report EPS of $0.70, down 5.41% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.44 billion, down 2.6% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.38 per share and revenue of $41.84 billion. These totals would mark changes of +1.81% and +3.5%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for SNY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.69% lower. SNY is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that SNY has a Forward P/E ratio of 15.02 right now. This valuation marks a discount compared to its industry's average Forward P/E of 15.2.
It is also worth noting that SNY currently has a PEG ratio of 2.07. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.07 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 17, which puts it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.